Assetmark, Inc United Therapeutics Corp Transaction History

Assetmark, Inc

$34.9 Billion
Q3 2024

A detailed history of Assetmark, Inc transactions in United Therapeutics Corp stock. As of the latest transaction made, Assetmark, Inc holds 419,957 shares of UTHR stock, worth $155 Million. This represents 0.43% of its overall portfolio holdings.

Number of Shares

419,957

Previous 267,708 56.87%

Holding current value

$155 Million

Previous $85.3 Million 76.47%

% of portfolio

0.43%

Previous 0.27%

34 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	BUY	$311.04 - $363.55 $47.4 Million - $55.4 Million	152,249 Added 56.87%	419,957 $150 Million
Q2 2024 Aug 13, 2024	SELL	$228.26 - $319.04 $560,150 - $782,924	-2,454 Reduced 0.91%	267,708 $85.3 Million
Q1 2024 May 06, 2024	SELL	$210.76 - $249.51 $453,977 - $537,444	-2,154 Reduced 0.79%	270,162 $62.1 Million
Q4 2023 Feb 09, 2024	BUY	$214.88 - $256.94 $448,669 - $536,490	2,088 Added 0.77%	272,316 $59.9 Million
Q3 2023 Oct 27, 2023	SELL	$211.82 - $248.24 $2.41 Million - $2.82 Million	-11,368 Reduced 4.04%	270,228 $61 Million
Q2 2023 Aug 11, 2023	BUY	$205.19 - $232.99 $2.29 Million - $2.6 Million	11,173 Added 4.13%	281,596 $62.2 Million
Q1 2023 May 05, 2023	BUY	$212.99 - $276.17 $6.4 Million - $8.3 Million	30,060 Added 12.51%	270,423 $60.6 Million
Q4 2022 Feb 10, 2023	SELL	$205.95 - $280.43 $5.35 Million - $7.29 Million	-25,992 Reduced 9.76%	240,363 $66.8 Million
Q3 2022 Nov 01, 2022	BUY	$203.3 - $244.17 $10.9 Million - $13.1 Million	53,855 Added 25.34%	266,355 $55.8 Million
Q2 2022 Aug 03, 2022	SELL	$174.81 - $241.14 $7.84 Million - $10.8 Million	-44,831 Reduced 17.42%	212,500 $50.1 Million
Q1 2022 May 13, 2022	SELL	$166.16 - $213.96 $490,005 - $630,968	-2,949 Reduced 1.13%	257,331 $46.2 Million
Q4 2021 Feb 14, 2022	BUY	$184.32 - $216.08 $3.09 Million - $3.63 Million	16,785 Added 6.89%	260,280 $56.2 Million
Q3 2021 Nov 12, 2021	BUY	$179.86 - $214.88 $5.14 Million - $6.14 Million	28,563 Added 13.29%	243,495 $44.9 Million
Q2 2021 Aug 16, 2021	BUY	$170.47 - $211.93 $4.18 Million - $5.19 Million	24,510 Added 12.87%	214,932 $38.6 Million
Q1 2021 May 14, 2021	BUY	$153.94 - $174.85 $499,381 - $567,213	3,244 Added 1.73%	190,422 $31.9 Million
Q4 2020 Feb 10, 2021	BUY	$101.87 - $151.79 $1.75 Million - $2.61 Million	17,217 Added 10.13%	187,178 $28.4 Million
Q3 2020 Nov 13, 2020	BUY	$99.9 - $121.13 $9.91 Million - $12 Million	99,247 Added 140.35%	169,961 $17.2 Million
Q2 2020 Aug 11, 2020	BUY	$92.74 - $125.82 $6.55 Million - $8.89 Million	70,617 Added 72801.03%	70,714 $8.21 Million
Q1 2020 May 12, 2020	BUY	$79.39 - $115.35 $5,001 - $7,267	63 Added 185.29%	97 $9,000
Q4 2019 Feb 11, 2020	BUY	$78.31 - $95.34 $2,662 - $3,241	34 New	34 $3,000
Q3 2019 Nov 13, 2019	SELL	$74.85 - $85.99 $17,365 - $19,949	-232 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$76.06 - $120.81 $1,064 - $1,691	14 Added 6.42%	232 $18,000
Q4 2018 Feb 13, 2019	SELL	$101.4 - $128.73 $40,661 - $51,620	-401 Reduced 64.78%	218 $24,000
Q3 2018 Nov 13, 2018	BUY	$113.81 - $129.46 $9,332 - $10,615	82 Added 15.27%	619 $79,000
Q2 2018 Aug 01, 2018	BUY	$101.14 - $118.31 $8,900 - $10,411	88 Added 19.6%	537 $61,000
Q1 2018 May 16, 2018	BUY	$107.21 - $151.94 $3,001 - $4,254	28 Added 6.65%	449 $50,000
Q4 2017 Feb 13, 2018	SELL	$118.58 - $151.28 $355 - $453	-3 Reduced 0.71%	421 $62,000
Q3 2017 Nov 08, 2017	SELL	$114.6 - $136.81 $49,163 - $58,691	-429 Reduced 50.29%	424 $50,000
Q2 2017 Aug 15, 2017	BUY	N/A	351 Added 69.92%	853 $110,000
Q1 2017 Sep 15, 2017	BUY	N/A	420 Added 512.2%	502 $67,000
Q4 2016 Sep 15, 2017	SELL	N/A	-66 Reduced 44.59%	82 $12,000
Q3 2016 Sep 15, 2017	SELL	N/A	-46 Reduced 23.71%	148 $18,000
Q2 2016 Sep 15, 2017	BUY	N/A	189 Added 3780.0%	194 $20,000
Q4 2015 Sep 15, 2017	BUY	N/A	5	5 $1,000

Others Institutions Holding UTHR

# of Institutions

672

Shares Held

42.4M

Call Options Held

194K

Put Options Held

295K

View Full List

About UNITED THERAPEUTICS Corp

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.8B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

More about UTHR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Account